Rare Diseases Are Only Rare
If You Don’t Live with One®
Quoin Pharmaceuticals
Quoin is a clinical-stage specialty pharmaceutical company focused on developing therapeutic products for rare and orphan diseases. We are dedicated to supporting underserved patients, their families, communities, and care teams around the world.
The challenges associated with living with rare and orphan diseases, which affect about 300 million people globally, are profound. Our mission is simple: to bring hope where there is currently none.
Our global reach includes exclusive marketing and distribution partnerships spanning more than 60 countries, augmenting our planned commercial infrastructure in the U.S. and Western Europe.
News
Featured News
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin...
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study Target Current Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ Treatment Investigator’s Global Assessment (IGA)...
TRIALS
Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals is developing QRX003, a topical lotion designed to address the underlying mechanisms of Netherton Syndrome. Currently, Quoin is conducting four ongoing investigational studies evaluating QRX003’s safety, efficacy, and potential as the first approved treatment for this devastating condition.
Patients and families interested in participating or receiving updates can sign up for alerts Here.
A Commitment to the Netherton Syndrome Community
At Quoin, patients are at the heart of everything we do. We are steadfast in our commitment to delivering life-changing therapies and providing the first-ever approved treatment for Netherton Syndrome. For us, the message is clear: We will not stop until we succeed.
For more information about Quoin’s clinical trials, visit:
About Quoin’s Clinical Trials
CL-QRX003-001: Double-Blind, Placebo-Controlled Study
- Objective: Assess QRX003 compared to a placebo in patients 14 and older.
- Design: Topical application twice daily for 12 weeks to pre-designated areas of the body. Subjects must completely wash-out of all systemic therapy prior to initiation of the study.
- Endpoints: Includes Investigator’s Global Assessment (IGA), Worst Itch score, Skin Severity Index score, and Patient Assessment.
CL-QRX003-002: Open-Label Study
- Objective: Evaluate QRX003 as an adjuvant therapy for NS patients currently using systemic biologics for symptomatic relief.
- Design: Topical application twice daily for 12 weeks. Subjects must currently be on off-label systemic therapy and remain on those during the study period.
- Endpoints: Includes Investigator’s Global Assessment (IGA), Worst Itch score, Skin Severity Index score, and Patient Assessment.
All subjects receive test material
CL-QRX003-003: Whole-Body Clinical Study
- Conducted by Dr. Amy Paller at Northwestern University, a globally recognized expert and KOL about this disease.
- Design: Topical application to greater than 80% of the body surface area twice daily for 12 weeks.
- Endpoints: Includes Investigator’s Global Assessment (IGA), Worst Itch score, Skin Severity Index score, and Patient Assessment.
- Goal: Generate real-world data to support potential FDA approval.
Pediatric Study
- First Subject in Ireland dosed
- Up to 3 Subjects in Spain dosed Q1’25
- Up to 6 subjects in UK dosed Q2’25
- All subjects receive test material
- Dosing is 2x/day to pre-defined areas
Patients and families interested in participating or receiving updates can sign up for alerts here.